Allogene therapeutics, inc. (ALLO)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18
Assets
Current assets:
Cash and cash equivalents

135,897

175,126

160,990

112,584

92,748

92,432

83,141

Short-term investments

357,026

355,407

340,254

389,840

373,392

366,952

161,080

Prepaid expenses and other current assets

11,491

14,043

8,513

9,118

10,487

8,598

3,132

Total current assets

504,414

544,576

509,757

511,542

476,627

467,982

247,353

Long-term investments

60,121

58,322

100,702

147,769

214,588

261,966

154,045

Operating lease right-of-use asset

43,836

44,495

31,437

31,880

32,394

33,015

24,996

Property and equipment, net

66,349

56,449

45,943

35,817

20,426

8,595

4,693

Intangible assets, net

0

151

301

452

603

754

904

Restricted cash

4,299

4,299

4,299

4,299

4,299

1,299

937

Other long-term assets

4,675

4,618

3,105

2,238

432

244

2,307

Equity method investment

4,800

4,892

-

-

-

0

-

Total assets

688,523

717,802

695,544

733,997

749,369

773,855

435,235

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

7,199

9,250

8,047

23,503

12,976

12,338

3,083

Accrued and other current liabilities

19,619

23,829

25,307

14,497

14,289

17,121

16,779

Convertible notes payable

-

-

-

-

-

-

139,615

Total current liabilities

26,818

33,079

33,354

38,000

27,265

29,459

159,477

Lease liability, noncurrent

51,536

51,349

37,689

34,867

34,811

34,456

25,661

Other long-term liabilities

3,650

4,351

4,785

5,495

6,065

6,776

7,488

Total liabilities

82,004

88,779

75,828

78,362

68,141

70,691

192,626

Commitments and Contingencies (Notes 6 and 7)

-

-

-

-

-

-

0

Convertible preferred stock, $0.001 par value; no shares and 1,000,000 shares authorized as of December 31, 2018 and December 31, 2017, respectively; no shares issued and outstanding as of December 31, 2018 and December 31, 2017

-

-

-

-

-

-

411,052

Stockholders’ equity:
Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2020 and December 31, 2019; no shares were issued and outstanding as of March 31, 2020 and December 31, 2019

0

0

0

0

-

0

-

Common stock, $0.001 par value: 200,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 125,262,537 and 124,267,358 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

125

124

122

122

121

121

31

Additional paid-in capital

1,055,386

1,023,876

952,820

937,709

922,816

914,265

12,693

Accumulated deficit

-450,600

-396,122

-335,100

-284,357

-243,114

-211,528

-181,019

Accumulated other comprehensive income

1,610

1,145

1,866

2,161

1,405

306

-148

Total stockholders’ equity

606,519

629,023

619,716

655,635

681,228

703,164

-168,443

Total liabilities and stockholders’ equity

688,523

717,802

695,544

733,997

749,369

773,855

435,235